Adma Biologics reported $80.75M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Adma Biologics USD 80.75M 8.07M Mar/2026
Alnylam Pharmaceuticals USD 992.69M 167.68M Jun/2026
BioCryst Pharmaceuticals USD 214.41M 61.36M Jun/2026
Minerva Neurosciences -4.27M 26.79M Dec/2024
Novavax USD 125.04M 76.09M Dec/2025
Omeros USD -33.16M 18.52M Jun/2024
Takeda JPY 813.22B 124.39B Jun/2026